What Is AOD9604?
AOD9604 (Anti-Obesity Drug 9604) is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH 177–191). It was originally developed by researchers at Monash University in Australia seeking to isolate the lipolytic properties attributed to hGH without the growth-promoting or diabetogenic effects associated with full-length GH. AOD9604 does not bind the classical growth hormone receptor and does not stimulate IGF-1 production in the research models studied to date, making it a selective tool for investigating lipolytic pathway biology. TrueCanPeptides carries AOD9604 10mg for laboratory research purposes.
Learn more about research peptides →
Mechanism of Action
AOD9604 is thought to interact with beta-adrenergic receptors and lipolytic signalling cascades in adipose tissue models, stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat synthesis) in preclinical preparations — effects that parallel some actions attributed to native hGH at the metabolic level. Crucially, this is believed to occur independently of the GH receptor-IGF-1 axis, as AOD9604 lacks the structural elements required for GH receptor binding.
In adipocyte cell culture models and rodent studies, AOD9604 has been observed to activate beta-3 adrenergic receptor pathways and downstream cAMP-mediated signalling associated with lipolytic activity. The compound has also been examined in the context of lipid metabolism modelling, with preclinical data suggesting effects on fat cell differentiation and lipid accumulation.
Research Applications
AOD9604 has been investigated in the following preclinical and early translational research contexts:
- Lipolytic pathway research: Studied in adipocyte models for stimulation of lipolysis and inhibition of lipid synthesis independent of the GH-IGF-1 axis.
- Metabolic research: Examined in rodent obesity models where metabolic outcomes associated with lipolytic activity have been characterised.
- hGH fragment biology: Used as a tool compound to delineate structure-activity relationships in the C-terminal region of growth hormone.
- Body composition research: Investigated in preclinical models examining fat mass changes in response to lipolytic peptide interventions.
All AOD9604 applications are investigational. Visit the TrueCanPeptides Research Hub →
Storage & Handling
AOD9604 should be stored in lyophilised form at −20°C, away from moisture and direct light. Reconstitute in sterile water or an appropriate physiological buffer before use. Aliquot reconstituted solutions and store at −80°C. Minimise freeze-thaw cycles to preserve peptide integrity.
For full handling information, see the Peptide Storage Guide and quality and purity page.
Related Research
Researchers investigating metabolic and lipolytic pathways may also be interested in:
- 5-Amino-1MQ — NNMT inhibitor studied in adipogenesis and NAD+ metabolism research
- SLU-PP-332 — ERR agonist investigated in oxidative metabolism and exercise mimetic research
Disclaimer: This content is intended for educational and research purposes only. The compounds discussed on this page are not approved for human therapeutic use by Health Canada or any other regulatory authority. They are not intended to diagnose, treat, cure, or prevent any disease or medical condition. TrueCanPeptides supplies research compounds strictly for in vitro and laboratory research use. All information presented is derived from published preclinical and early-phase research literature and does not constitute medical advice. Consult a qualified healthcare professional before making any health-related decisions.